Immunotherapy of cancer for the elderly patient: Does allogeneic bone marrow transplantation after nonmyeloablative conditioning provide a new option?

Cancer Immunology, Immunotherapy

Volumn 53, Issue 8, 2004, Pages 659-676

  Zöller, Margot ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

Age; Allogeneic bone marrow cell transplantation; Tumor; Vaccination

Indexed keywords

AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER; CANCER IMMUNOTHERAPY; CELL MATURATION; CLONAL ANERGY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

AGED; AGED, 80 AND OVER; ANIMALS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 3242731069     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (330)

1. Aguila HL, Akashi K, Domen J, Gandy KL, Lagasse E, Mebius RE, Morrison SJ, Shizuru J, Strober S, Uchda N, Wright DE, Weissman IL (1997) From stem cells to lymphocytes, biology and transplantation. Immunol Rev 160:15713
2. Akbar AN, Soares MV, Plunkett FJ, Salmon M (2000) Differential regulation of CD8+ T cell senescence in mice and men. Mech Ageing Dev 121:69
3. Alberola-Ila J, Takaki S, Kerner JD, Perlmutter RM (1997) Differential signaling by lymphocyte antigen receptors. Annu Rev Immunol 15:125
4. Albi N, Ruggeri, L, Aversa F, Merigiola C, Tosti A, Tognellini R, Grossi CE, Martelli MF, Velardi A (1996) Natural killer (NK) cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "three loci" HLA incompatible bone marrow transplantation. Blood 87:3993
5. Altenschmidt U, Moritz D, Groner B (1997) Specific cytotoxic T lymphocytes in gene therapy. J Mol Med 75:259
6. Anderson LD Jr, Savary CA, Mullen CA (2000) Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 95:2426
7. Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411:385
8. Appella E, Loftus DJ, Sakaguchi K, Sette A, Celis E (1995) Synthetic antigenic peptides as a new strategy for immunotherapy of cancer. Biomed Pept Proteins Nucleic Acids 1:177
9. Arina A, Tirapu I, Alfaro C, Rodriguez-Calvillo M, Mazzolini G, Inoges S, Lopez A, Feijoo E, Bendandi M, Melero I (2002) Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. Exploiting cross-priming. Exp Hematol 30:1355
10. Armstrong TD, Clements VK, Ostrand-Rosenberg S (1998) MHC class II transfected tumor cells directly present antigen to tumor specific CD4+ T lymphocytes. J Immunol 160:661
11. Armstrong AC, Eaton D, Ewing JC (2002) Cellular vaccine therapy for cancer. Expert Rev Vaccines 1:303
12. Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O (2002) Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther 5:609
13. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E (1997) Bone marrow generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1771
14. Aspinall R, Andrew D (2000) Immunosenescence: potential causes and strategies for reversal. Biochem Soc Trans 28:250
15. Aspinall R, Andrew D (2000) Thymic involution in aging. J Clin Immunol 20:250
16. Azuma M, Lanier LL (1995) The role of CD28 costimulation in the generation of cytotoxic T lymphocytes. Curr Top Microbiol Immunol 198:59
17. Bakker AB, Marland G, deBoer AJ, Huijbens RJ, Danen EH, Adema GJ, Figdor CG (1995) Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma associated antigen derived epitopes by dendritic cells in vitro. Cancer Res 55:5330
18. Bakker AB, Phillips JH, Figdor CG, Lanier LL (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen specific CTL. J Immunol 160:5239
19. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor derived dendritic cell vaccine. Cancer Res 61:6451
20. Barda-Saad M, Rozenszajn LA, Globerson A, Zhang AS, Zipori D (1996) Selective adhesion of immature thymocytes to bone marrow stromal cells: relevance to T cell lymphopoiesis. Exp Hematol 24:386
21. Barrettt AJ (2000) Conditioning regimens for allogeneic stem cell transplants. Curr Opin Hematol 7:339
22. Barsoukov AA, Moore PF, Storb R, Santos EB, Sandmaier BM (1999) The use of an anti TCRalphabeta monoclonal antibody to control host versus graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation 67:1329
23. Barta A, Denes R, Masszi T, Remenyi P, Batai A, Torbagyi E, Sipos A, Lengyel L, Jakab K, Gyodi E, Reti M, Foldi J, Paldi-Haris P, Avalos M, Paloczi K, Fekete S, Torok J, Hoffer I, Jakab J, Varadi G, Kelemen E, Petranyi G (2001) Remarkably reduced transplant related complications by dibromomannitol non myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. Acta Haematol 105:64
24. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S (1996) Rejection of MHC class II transfected tumor cells requires induction of tumor encoded B7 1 and/or B7 2 costimulatory molecules. J Immunol 156:3821
25. Bennett AR, Farley A, Blair NF, Gordon J, Sharp L, Blackburn CC (2002) Identification and characterization of thymic epithelial progenitor cells. Immunity 16:803
26. Bennett JM, Sahasrabudhe DM, Hall WJ (1997) Medical oncology and geriatric medicine: is it time for fellowship integration? Cancer 80:1351
27. Berinstein N (2003) Overview of therapeutic vaccination approaches for cancer. Semin Oncol 30:1
28. Berlyn KA, Ponniah S, Stass SA, Malone JG, Hamlin-Green G, Lim JK, Cottler-Fox M, Tricot G, Alexander RB, Mann DL, Malone RW (1999) Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy. J Biotechnol 73:155
29. Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM (1998) Cytokine production after influenza vaccination in a healthy elderly population. Vaccine 16:1722
30. Berzins SP, Boyd RL, Miller JF (1998) The role of the thymus and recent thymic migrants in the maintenance of the adult peripheral lymphocyte pool. J Exp Med 187:1839
31. Berzins SP, Uldrich AP, Sutherland JS, Gill J, Miller JF, Godfrey DI, Boyd RL (2002) Thymic regeneration: teaching an old immune system new tricks. Trends Mol Med 8:469
32. Betolino P, Rabourdin-Combe C (1996) The MHC class II associated invariant chain. A molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. Crit Rev Immunol 16:359
33. Beverley PC, Grubeck-Loebenstein B (2000) Is immune senescence reversible? Vaccine 18:1721
34. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell RA, Korngold R, Noelle R, Vallera DAJ (1997) Blockade of CD40 ligand CD40 interaction impairs CD4+ T cell mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol 158:29
35. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279:349
36. Bonafe M, Valensin S, Gianni W, Marigliano V, Franceschi C (2001) The unexpected contribution of immunosenescence to the leveling off of cancer incidence and mortality in the oldest old. Crit Rev Oncol Hematol 39:227
37. Bornhauser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R, Freiberg-Richter J, Rollig C, Geissler G, Lutterbeck K, Oelschlagel U, Ehninger G (2001) Dose reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 7:2254
38. Bremers AJ, Parmiani G (2000) Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 34:1
39. Briones J, Timmerman JM, Panicalli DL, Levy R (2003) Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst 95:548
40. Bronte V (2001) Genetic vaccination for the active immunotherapy of cancer. Curr Gene Ther 1:53
41. Brooks AG, Boyington JC, Sun PD (2000) Natural killer cell recognition of HLA class I molecules. Rev Immunogenet 2:433
42. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA A2 restricted T cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309
43. Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Tonks S, Murray N, Bodmer J, Bodmer W (1996) Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 47:364
44. Bruhns P, Marchetti P, Fridman W.H, Vivier E, Daeron M (1999) Differential roles of N and C terminal immunoreceptor tyrosine based inhibition motifs during inhibition of cell activation by killer cell inhibitory receptors. J Immunol 162:3168
45. Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, Myers LA, Ward FE (1999) Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340:508
46. Burshtyn DN, Shin J, Stebbins C, Long EO (2000) Adhesion to target cells is disrupted by the killer cell inhibitory receptor. Curr Biol 10:777
47. Cambiaggi A, Verthuy C, Naquet P, Romagne F, Ferrier P, Biassoni R, Moretta A, Moretta L, Vivier E (1997) Natural killer cell acceptance of H 2 mismatch bone marrow grafts in transgenic mice expressing HLA Cw3 specific killer cell inhibitory receptor. Proc Natl Acad Sci U S A 94:8088
48. Campbell KS, Cella M, Carretero M, Lopez-Botet M, Colonna M (1998) Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex. Eur J Immunol 28:599
49. Castelli C, Rivoltin L, Mazzocchi A, Parmian G (1997) T cell recognition of melanoma antigens and its therapeutic applications. Int J Clin Lab Res 27:103
50. Castellino F, Zhong G, Germain RN (1997) Antigen presentation by MHC class II molecules, invariant chain function, protein trafficking and the molecular basis of diverse determinant capture. Hum Immunol 54:159
51. Chakravarti B, Abraham G (1999) Aging and T-cell-mediated immunity. Mech Ageing Dev 108:183
52. Chakravarti B, Chakravarti DN, Devecis J (1998) Effect of age on mitogen induced protein tyrosine phospjorylation in human T cell and its subsets: down-regulation of tyrosine phosphorylation of ZAP-70. Mech Ageing Dev 104:41
53. Chambers CA, Allison JP (1997) Co-stimulation in T cell responses. Curr Opin Immunol 9:396
54. Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kurman RJ, Pardoll DM, Wu T (2000) Antigen specific cancer immunotherapy using a GM GSF secreting allogeneic tumor cell based vaccine. Int J Cancer 86:725
55. Chattergoon MA, Robinson TM, Boyer JD, Weiner DB (1998) Specific immune induction following DNA based immunization through in vivo transfection and activation of macrophages/antigen presenting cells. J Immunol 160:5707
56. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P (1999) Identification of MAGE 3 epitopes presented by HLA DR molecules to CD4(+) T lymphocytes. J Exp Med 189:767
57. Chen L (1997) Manipulation of T cell response to tumors by targeting on costimulatory pathways. Leukemia 3:567
58. Childs RW (2001) Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma. Crit Rev Immunol 21:191
59. Childs R, Barrett J (2002) Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. Semin Hematol 39:63
60. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J (1999) Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral blood progenitor cell transplant, evidence for a graft versus tumor effect. J Clin Oncol 17:2044
61. Cochlovius B, Linnebacher M, Zewe-Welschof M, Zöller M (1999) Recombinant gp100 protein presented by dendritic cells elicits a T helper cell response in vitro and in vivo. Int J Cancer 83:547
62. Cochlovius B, Stassar M, Christ O, Radrazzini L, Hammer J, Mytilineos I, Zöller M (2000) Selection, presentation and response towards MHC class II restricted peptides of the melanoma associated gp100 protein. J Immunol 165:4581
63. Coley W (1896) Further observations upon the treatment of malignant tumors with the toxins of erysipelas and bacillus prodigious with a report of 160 cases. Johns Hopkins Hosp Bull 7:157
64. Condiotti R, Nagler A (1996) Campath 1G impairs human natural killer (NK) cell mediated cytotoxicity. Bone Marrow Transplant 18:713
65. Conrad C, Nestle FO (2003) Dendritic cell-based cancer therapy. Curr Opin Mol Ther 5:405
66. Coulie PG, van der Bruggen P (2003) T-cell responses of vaccinated cancer patients. Curr Opin Immunol 15:131
67. Cutler C, Antin JH (2001) Peripheral blood stem cells for allogeneic transplantation, a review. Stem Cells 19:108
68. Damjanovich S, Gaspar R Jr, Bene L, Jenei A, Matyus L (2003) Signal transduction in T lymphocytes and aging. Exp Gerontol 38:231
69. Dansey RD, Baynes RD (2001) Nonablative allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 13:27
70. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, Chakraborty T, Weiss S (1997) Oral somatic transgene vaccination using attenuated S.thyphimurium. Cell 91:765
71. Davis CB, Gillies SD (2003) Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol Immunother 52:297
72. Dazzi F, Goldman JM (1998) Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu Rev Med 49:329
73. De Visser KE, Schumacher TN, Kruisbeek AM (2003) CD8+ T cell tolerance and cancer immunotherapy. J Immunother 26:1
74. DeBruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, deCock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijftout JW, Ottenhoff TH, Offringa R, Melief CJ (1998) Immunization with human papillomavirus type 16 (HPV16) oncoprotein loaded dendritic cells as well as protein in adjuvant induces MHC class I restricted protection to HPV16 induced tumor cells. Cancer Res 58:724
75. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, Peschel C (2000) Immunostimulatory CpG oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95:999
76. DePlaen E, Lurquin C, Lethe B, van derBruggen P, Brichard V, Renauld JC, Coulie P, VanPel A, Boon T (1997) Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods 12:125
77. Devine SM, Adkins DR, Khoury H, Brown RA. Vij R, Blum W, DiPersio JF (2003) Recent advances in allogeneic hematopoietic stem-cell transplantation. J Lab Clin Med 141:7
78. Dillman RO (2003) Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin Oncol 30:434
79. Disis ML, Grabstein KH, Sleath PR, Cheever MA (1999) Generation of immunity to the HER 2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide based vaccine. Clin Cancer Res 5:1289
80. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ, Koup RA (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396:690
81. Dredge K, Dalgleish AG, Marriott JB (2003) Angiogenesis inhibitors in cancer therapy. Curr Opin Investig Drugs 4:667
82. Drobyski WR (2000) Evolving strategies to addess adverse transplant outcomes associated with T cell depletion. J Hematother Stem Cell Res 9:327
83. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666
84. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN (2002) T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 110:185
85. Effros RB (2000) Costimulatory mechanisms in the elderly. Vaccine 18:1661
86. Effros RB (2003) Genetic alterations in the ageing immune system: impact on infection and cancer. Mech Ageing Dev 124:71
87. Effros RB, Pawelec G (1997) Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Immunol Today 18:450
88. Effros RB, Cai Z, Linton PJ (2003) CD8 T cells and aging. Crit Rev Immunol 23:45
89. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW (2002) Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 188:136
90. Engelhard VH (1994) Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 12:181
91. Engleman EG (2003) Dendritic cell-based cancer immunotherapy. Semin Oncol 30:23
92. Ershler WB, Longo DL (1997) Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 89:1489
93. Fang B, Roth JA (2003) Tumor-suppressing gene therapy. Cancer Biol Ther 2:115
94. Farag SS, Fehniger TA, Becknell B, Blaser BW, Caligiuri MA. (2003) New directions in natural killer cell-based immunotherapy of human cancer. Expert Opin Biol Ther 3:237
95. Fassas AB, Morris C, Badros A, Van Rhee F, Tricot G (2002) Separating graft-versus-tumor from graft-versus-host reactions. Leuk Lymphoma 43:725
96. Fedorocko P, Hoferova Z, Hofer M, Brezani P (2003) Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities. Neoplasma 50:176
97. Fehse B, Goldmann M, Frerk O, Bulduk M, Zander AR (2000) Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant 26:39
98. Ferrara JL (2000) Pathogeneisis of acute graft versus host disease, cytokines and cellular effectors. J Hematother Stem Cell Res 9:299
99. Foss FM (2002) Immunologic mechanisms of antitumor activity. Semin Oncol 29:5
100. Fowler DH, Gress RE (2000) Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 38:221
101. Franceschi C, Bonafe M, Valensin S (2000) Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 18:1717
102. Fulop T, Leblanc C, Lacombe G, Dupuis G (1995) Cellular distribution of protein kinase C isoenzymes in CD3-mediated stimulation of human T lymphocytes with aging. FEBS Lett 375:69
103. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL (1993) DNA vaccines, protective immunization by parenteral, mucosal and gene gun inoculations. Proc Natl Acad Sci U S A 90:11478
104. Gabrilovich D, Pisarev V (2003) Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 4:525
105. Gabrilovich DI (2002) Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther 4:452
106. Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, Fernando GJ (2002) Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 62:6438
107. Garcia GG, Miller RA (1998) Increased Zap-70 association with CD3zeta in CD4 T cells from old mice. Cell Immunol 190:91
108. Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195:346
109. Garcia-Ojeda ME, Dejbakhsh-Jones S, Weissman IL, Strober S (1998) An alternate pathway for T cell development supported by the bone marrow microenvironment: recapitulation of thymic maturation. J Exp Med 187:1813
110. Garderet L, Snell V, Przepiorka D, Schenk T, Lu JG, Marini F, Gluckman E, Andreeff M, Champlin RE (2000) Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 67:124
111. Gardner EM, Murasko DM (2002) Age-related changes in Type 1 and Type 2 cytokine production in humans. Biogerontology 3:271
112. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59:5356
113. Gill J, Malin M, Hollander GA, Boyd R (2002) Generation of a complete thymic microenvironment by MTS24(+) thymic epithelial cells. Nat Immunol 3:635
114. Gilliet M, Kleinhans M, Lantelme E, Schadendorf D, Burg G, Nestle FO (2003) Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood 102:36
115. Ginaldi L, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Martorelli V, Quaglino D (1999) The immune system in the elderly, II. specific cellular immunity. Immunol Res 20:109
116. Globerson A, Effros RB (2000) Ageing of lymphocytes and lymphocytes in the aged. Immunol Today 21:515
117. Goker H, Haznedarogu IC, Chao NJ (2001) Acute graft vs host disease, pathobiology and management. Exp Hematol 29:259
118. Gollob JA, Ritz J (1996) CD2 CD58 interaction, the control of T cell interleukin 12 responsiveness: adhesion molecules link innate and acquired immunity. Ann N Y Acad Sci 795:71
119. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe, D (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci U S A 95:6279
120. Gorgas G, Butch ER, Guan KL, Miller RA (1997) Diminished activation of the MAP kinase pathway in CD3-stimulated T lymphocytes from old mice. Mech Ageing Dev 94:71
121. Gravekamp C (2001) Tailoring cancer vaccines to the elderly: the importance of suitable mouse models. Mech Ageing Dev 122:1087
122. Grubeck-Loebenstein B, Wick G (2002) The aging of the immune system. Adv Immunol 80:243
123. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621
124. Gupta S (1989) Membrane signal transduction in T cells in aging humans. Ann N Y Acad Sci 568:277
125. Guyton KZ, Gorospe M, Wang X, Mock YD, Kokkonen GC, Liu Y, Roth GS, Holbrook NJ (1998) Age-related changes in activation of mitogen-activated protein kinase cascades by oxidative stress. J Invest Dermatol Symp Proc 3:23
126. Habal N, Gupta RK, Bilchik AJ, Yee R, Leopolde Z, Ye W, Elashoff RM, Morton DL (2001) CancerVax. an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 8:389
127. Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H (1997) Isolation of novel HLA DR restricted potential tumor associated antigens from the melanoma cell line FM3. Cancer Res 57:3238
128. Hargreaves DC, Hyman PL, Lu TT, Ngo VN, Bidgol A, Suzuki G, Zou YR, Littman DR, Cyster JG (2001) A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 194:45
129. Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N, Hanyu F (1996) Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma, comparison between LAK cell, CTL therapy. J Immunother 19:218
130. Hathcock KS, Weng NP, Merica R, Jenkins MK, Hodes R (1998) Antigen-dependent regulation of telomerase activity in murine T cells. J Immunol 160:5702
131. Hayes-Lattin BM, Maziarz RT, Beer TM (2001) Allogeneic stem-cell transplantation in renal-cell carcinoma. Curr Oncol Rep 3:433
132. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP (2000) The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 18:529
133. Hellstrand K, Brune M, Naredi P, Mellqvist UH, Hansson M, Gehlsen KR, Hermodsson S (2000) Histamine: a novel approach to cancer immunotherapy. Cancer Invest 18:347
134. Henderson B, Wilson M (1995) Modulins, a new class of cytokine inducing proinflammatory bacterial virulence factor. Inflamm Res 44:187
135. Hernandez JF, Cretin F, Lombard-Platet S, Salvi JP, Walchshofer N, Gerlier D, Paris J, Rabourdin-Combe C (1994) Critical residue combinations dictate peptide presentation by MHC class II molecules. Peptides 15:583
136. Hinterberger-Fischer M, Hinterberger W (2001) Blood stem cell transplantation for breast cancer, new approaches using pre- peri- post transplant immunotherapy. Expert Opin Biol Ther 1:1029
137. Hirokawa K, Utsuyama M, Kobayashi S (2001) Hypothalamic control of thymic function. Cell Mol Biol (Noisy-le-grand) 47:97
138. Hodes RJ, Hathcock KS, Weng NP (2002) Telomeres in T and B cells. Nat Rev Immunol 2:699
139. Hoerr I, Obst R, Rammensee HG, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1
140. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777
141. Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, Holland SM, Linton GF, Miller JA, Leitman SF, Read EJ, Malech HL (2001) Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T cell depleted hematopoietic allograft. N Engl J Med 344:881
142. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B cell lymphoma using autologous antigen pulsed dendritic cells. Nat Med 2:52
143. Huard B, Karlsson L (2000) KIR expression on self reactive CD8+ T cells is controlled by T cell receptor engagement. Nature 403:325
144. Hummel S, Wilms D, Vitacolonna M, Zöller M (2002) Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the non-myeloablatively conditioned tumor-bearing host. J Leukoc Biol 72:898
145. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357
146. Igney FH, Krammer PH (2002) Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71:907
147. Jamieson BD, Douek DC, Killian S, Hultin LE, Scripture-Adams DD, Giorgi JV, Marelli D, Koup RA, Zack JA (1999) Generation of functional thymocytes in the human adult. Immunity 10:569
148. Jankowski RA, Ilstad ST (1997) Chimerism and tolerance, from freemartin cattle and neonatal mice to humans. Hum Immunol 52:155
149. Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, Kurman RJ, Pardoll DM, Wu TC (1999) Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7 expressing tumors. Hum Gene Ther 10:2727
150. Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D (1998) T cell depleted allogeneic bone marrow transplantation for high risk non Hodgkin's lymphoma, clinical and molecular follow up. Bone Marrow Transplant 21:893
151. Kalos M (2003) Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 21:781
152. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM (1999) Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 163:6867
153. Kawai T, Wee SL, Bazin H, Latinne D, Phelan J, Boskovic S, Ko DS, Hong HZ, Mauiyyedi S, Nadazdin O, Abrahamian G, Preffer F, Colvin RB, Sachs DH, Cosimi AB (2000) Association of natural killer cell depletion with induction of mixed chimerism and allograft tolerance in non human primates. Transplantation 70:368
154. Kehry MR, Hodgkin PD (1994) B cell activation by helper T cell membranes. Crit Rev Immunol 14:221
155. Kendall MD, Fitzpatrick FT, Greenstein BD, Khoylou F, Safieh B, Hamblin A (1990) Reversal of ageing changes in the thymus of rats by chemical or surgical castration. Cell Tissue Res 261:555
156. Kershaw MH, Trapani JA, Smyth MJ (1995) Cytotoxic lymphocytes, redirecting the cell mediated immune response for the therapy of cancer. Ther Immunol 2:173
157. Kim J, Chwae YJ, Kim MY, Choi IH, Park JH, Kim SJ (1997) Molecular basis of HLA C recognition by p58 natural killer cell inhibitory receptors. J Immunol 159:3875
158. Kirk CJ, Miller RA (1998) Analysis of Raf-1 activation in response to TCR activation and costimulation in murine T-lymphocytes: effect of age. Cell Immunol 190:33
159. Kobayashi H, Omiya R, Ruiz M, Huarte E, Sarobe P, Lasarte JJ, Herraiz M, Sangro B, Prieto J, Borras-Cuesta F, Celis E (2002) Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 8:3219
160. Koch U, Korngold R (1997) A synthetic CD4 CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers. Blood 89:2880
161. Kolb HJ, Holler E (1997) Hematopoietic transplantation, state of the art. Stem Cells 15:1151
162. Kreiter S, Winkelmann N, Schneider PM, Schuler M, Fischer T, Ullmann AJ, Huber C, Derigs HG, Kolbe K (2001) Failure of sustained engraftment after non myeloablative conditioning with low dose TBI and T cell reduced allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 28:157
163. Kumar V, George T, Yu YY, Liu J, Bennett M (1997) Role of murine NK cells and their receptors in hybrid resistance. Curr Opin Immunol 9:52
164. Kunitomi A, Hori T, Imura A, Uchiyama T (2000) Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system. J Leukoc Biol 68:111
165. Lagoo-Deenadayalan S, Lagoo AS, Hardy KJ, Grimm EA (1992) Tumor recognition and lytic competence of IL 2 activated lymphocytes, regulation of both antibody independent and dependent cellular cytotoxicity via P75 IL 2 receptor. Lymphokine Cytokine Res 11:207
166. Lan F, Zeng D, Higuchi M, Huie P, Higgins JP, Strober S (2001) Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T cell antigen receptor alphabeta. J Immunol 167:2087
167. Lanier LL (2001) Face off the interplay between activating and inhibitory immune receptors. Curr Opin Immunol 13:326
168. Lee DJ, Corr M, Carson DA (1998) Control of immune responses by gene immunization. Ann Med 30:460
169. Lee LA, Sergio JJ, Sykes M (1996) Natural killer cells weakly resist engraftment of allogeneic, long term, multilineage repopulating hematopoietic stem cells. Transplantation 61:125
170. Leitner WW, Thalhamer J (2003) DNA vaccines for non-infectious diseases: new treatments for tumour and allergy. Expert Opin Biol Ther 3:627
171. Leu RW, Zhou AQ, Shannon BJ, Herriott MJ (1990) Inhibitors of Clq biosynthesis suppress activation of murine macrophages for both antibody independent and antibody dependent tumor cytotoxicity. J Immunol 144:2281
172. Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL (2002) Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer 102:629
173. Lin KY, Guarnieri F, Staneley-O'Carroll K, Levitsky HI, August JT, Pardoll DM, Wu TC (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21
174. Liu J, Morris MA, Nguyen P, George TC, Koulich E, Lai WC, Schatzle JD, Kumar V, Bennett M (2000) Ly49I NK cell receptor transgene inhibition of rejection of H2b mouse bone marrow transplants. J Immunol 164:1793
175. Liu K (2003) Breakthroughs in cancer gene therapy. Semin Oncol Nurs 19:217
176. Liu K, Hodes RJ, Weng NP (2001) Cutting edge: telomerase activation in
177. Livak F, Schatz DG (1996) T-cell receptor alpha locus V(D)J recombination by-products are abundant in thymocytes and mature T cells. Mol Cell Biol 16:609
178. Locatelli F, Rondelli D, Burgio GR (2000) Tolerance an hematopoietic stem cell transplantation 50 yars after Burnet's theory. Exp Hematol 28:479
179. Long EO, Burshtyn DN, Clark WP, Peruzzi M, Rajagopalan S, Rojo S, Wagtmann N, Winter CC (1997) Killer cell inhibitory receptors, diversity, specificity, and function. Immunol Rev 155:135
180. Lovik G, Vaage JT, Rolstad B, Naper C (2001) The effect of in vivo depletion of NKR P1+ or CD8+ lymphocytes on the acute rejection of allogeneic lymphocytes (ALC) in the rat. Scand J Immunol 54:341
181. Lowdell MW, Lamb L, Hoyle C, Velardi A, Prentice HG (2001) Non MHC restricted cytotoxic cells, their roles in the control and treatment of leukaemias. Br J Haematol 114:11
182. Lowdell MW, Craston R, Prentice HG (1999) Generation of autologous immunity to acute myeloid leukaemia and maintenance of complete remission following interferon-alpha treatment. Cytokines Cell Mol Ther 5:119
183. Lundstrom K (2003) Alphavirus vectors for vaccine production and gene therapy. Expert Rev Vaccines 2:447
184. Luznik L, Fuchs EJ (2002) Donoar lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cane Contr 9:123
185. Lysaght J, Todryk S (2003) Developments in cancer vaccination. Curr Opin Investig Drugs 4:716
186. Machiels JP, van Baren N, Marchand M (2002) Peptide-based cancer vaccines. Semin Oncol 29:494
187. Mackall CL, Hakim FT, Gress RE (1997) Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol 9:339
188. Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, Gress RE (2001) IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood 97:1491
189. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT (1996) New treatment options for patients with melanoma, review of melanoma derived T cell epitope based peptide vaccines. Melanoma Res 6:11
190. Mahvi DM, Burkholder JK. Turner J. Culp J. Malter JS. Sondel PM, Yang NS (1996) Particle mediated gene transfer of granulocyte macrophage colony stimulating factor cDNA to tumor cells, implications for a clinically relevant tumor vaccine. Hum Gene Ther 7:1535
191. Maier S, Tertilt C, Chambron N, Gerauer K, Huser N, Heidecke CD, Pfeffer K (2001) Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28 / mice. Nat Med 7:557
192. Mandelboim O, Vadai E, Feldman M, Eisenbach L (1995) Expression of two H 2 K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells. Gene Ther 2:757
193. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP (1999) Melanoma cells present a MAGE 3 Epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:871
194. Manzo G (1998) The cancer process as a type of immunocomplex hypersensibility involving C3b, natural killer cytotoxicity and antibody dependent cell cytotoxicity, proposals for tumour immunotherapy and vaccine. Med Hypoth 50:409
195. Maris M, Storb R (2002) Outpatient allografting in hematologic malignancies and nonmalignant disorders-applying lessons learned in the canine model to humans. Cancer Treat Res 110:149
196. Martin PJ, Rowley SD, Anasetti C, Chauncey TR, Gooley T, Petersdorf EW, van Burik JA, Flowers ME, Storb R, Appelbaum FR, Hansen JA (1999) A phase I/II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA mismatched unrelated recipients. Blood 94:2192
197. Mashino K, Sadanaga N, Tanaka F, Ohta M, Yamaguchi H, Mori M (2002) Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity. Mol Cancer Ther 1:785
198. Matthes-Martin S, Mann G, Peters C, Lion T, Fritsch G, Haas OA, Potschger U, Gadner H (2000) Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia, a single centre experience and review of the literature. Bone Marrow Transplant 26:377
199. McCarthy NJ, Bishop MR (2000) Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. Oncologist 5:48
200. McLeod JD (2000) Apoptotic capability in ageing T cells. Mech Ageing Dev 121:151
201. Mielcarek M, Sandmaier BM, Maloney DG, Maris M, McSweeney PA, Woolfrey A, Chauncey T, Feinstein L, Niederwieser D, Blume KG, Forman S, Torok-Storb B, Storb R (2002) Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. J Clin Immunol 22:70
202. Miller RA (2000) Effect of aging on T lymphocyte activation. Vaccine 18:1654
203. Miller RA, Stutman O (1984) T cell repopulation from functionally restricted splenic progenitors: 10,000-fold expansion documented by using limiting dilution analyses. J Immunol 133:2925
204. Mitchell DA, Nair SK (1998) RNA transfected dendritic cells as cancer vaccines. Curr Opin Mol Ther 2:176
205. Mitchell MS (1998) Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25:623
206. Mitchell MS (2003) Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 52:686
207. Mongini C, Sanchez-Lockhart M, Waldner CI, Alvarez EM, Gravisaco MJ, Roig MI, Hajos SE (1996) Enhancement of anti tumor immunity in syngeneic mice after MHC class II gene transfection. Br J Cancer 74:258
208. Morecki S, Gelfand Y, Nagler A, Condiotti R, Nabet C, Ackerstein A, Slavin S (2001) Activated long term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients. Bone Marrow Transplant 28:243
209. Muller-Hermelink HK, Sale GE, Borisch B, Storb R (1987) Pathology of the thymus after allogeneic bone marrow transplantation in man: a histologic immunohistochemical study of 36 patients. Am J Pathol 129:242
210. Murphy WJ, Koh CY, Raziuddin A, Bennett M, Longo DL (2001) Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol Rev 181:279
211. Murthy VL, Stern LJ (1997) The class II MHC protein HLA DR1 in complex with an endogenous peptide, implications for the structural basis of the specificity of peptide binding. Structure 5:1385
212. Neipp M, Gammie JS, Exner BG, Li S, Chambers WH, Pham SM, Ildstad ST (1999) A partial conditioning approach to achieve mixed chimerism in the rat, depletion of host natural killer cells significantly reduces the amount of total body irradiation required for engraftment. Transplantation 68:369
213. Nelson RP Jr, Ballow M (2003) 26. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. J Allergy Clin Immunol 111:720
214. Nemunaitis J (2003) GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. J Control Release 91:225
215. Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA (2001) Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res 61:6178
216. Nikolic B, Cooke DT, Zhao G, Sykes M (2001) Both gamma delta T cells and NK cells inhibit the engraftment of xenogeneic rat bone marrow cells and the induction of xenograft tolerance in mice. J Immunol 166:1398
217. Ochsenbein AF (2002) Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther 9:1043
218. O'Connell J, Bennett MW, Nally K, Houston A, O'Sullivan GC, Shanahan F (2000) Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci 910:178
219. Ohnmacht GA, Marincola FM (2000) Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. J Cell Physiol 182:332
220. Olsen AC, Fossum B, Kirkin AF, Zeuthen J, Gaudernack G (1995) A human melanoma line recognized by both HLA class I and II restricted T cells is capable of initiating both primary and secondary immune responses. Scand J Immunol 41:357
221. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693
222. Ostrand-Rosenberg S, Pularski BA, Clements VK, Qi L, Pipeling MR, Hanyok LA (1999) Cell based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev 170:101
223. Ottonello L, Morone P, Dapino P, Dallegri F (1996) Monoclonal Lym 1 antibody dependent lysis of B lymphoblastoid tumor targets by human complement and cytokinine exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood 87:5171
224. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP (1998) gp100/pmel17 is a murine tumor rejection antigen, induction of self reactive, tumoricidal T cells using high affinity, altered peptide ligand. J Exp Med 188:277
225. Pachuk CJ, McCallus DE, Weiner DB, Satishchandran C (2000) DNA vaccines challenges in delivery. Curr Opin Mol Ther 2:188
226. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317
227. Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP (1998) Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium results in protective immunity against a murine fibrosarcoma. Blood 92:3172
228. Pahlavani MA, Richardson A (1996) The effect of age on the expression of interleukin 2. Mech Ageing Dev 89:125
229. Pan ZK, Weiskirch LM, Paterson Y (1999) Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res 59:5264
230. Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807
231. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399
232. Parker KC, Shields M, DiBrino M, Brooks A, Coligan JE (1995) Peptide binding to MHC class I molecules, implications for antigenic peptide prediction. Immunol Res 14:34
233. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94:805
234. Parmiani G, Rivoltini L, Andreola G, Carrabba M (2003) Cytokines in cancer therapy. Immunol Lett 74:41
235. Patel DD, Gooding ME, Parrott RE, Curtis KM, Haynes BF, Buckley RH (2000) Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 342:1325
236. Pawelec G (2000) Hypothesis: loss of telomerase inducibility and subsequent replicative senescence in cultured human T cells is a result of altered costimulation. Mech Ageing Dev 121:181
237. Pawelec G, Rees RC, Kiessling R, Madrigal A, Dodi A, Baxevanis C, Gambacorti-Passerini C, Masucci G, Zeuthen J (1999) Cells and cytokines in immunotherapy and gene therapy of cancer. Crit Rev Oncog 10:83
238. Pawelec G, Hirokawa K, Fulop T (2001) Altered T cell signalling in ageing. Mech Ageing Dev 122:1613
239. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, Sykes M (1999) Lymphohematopoietic graft vs. host reactions can be induced without graft vs. host disease in murine mixed chimeras established with a cyclophosphamide based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 5:133
240. Pende D, Accame L, Pareti L, Mazzocchi A, Moretta A, Parmiani G, Moretta L (1998) The susceptibility to natural killer cell mediated lysis of HLA class I positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol 28:2384
241. Piemonti L, Zerbi A, Di Carlo V (2003) Strategies for tumor immune escape. Drugs Today (Barc) 39:701
242. Pietersz GA, Apostolopoulos V, McKenzie IF (2000) Generation of cellular immune responses to antigenic tumor peptides. Cell Mol Life Sci 57:290
243. Ponsaerts P, Van den Bosch G, Cools N, Van Driessche A, Nijs G, Lenjou M, Lardon F, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF (2002) Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol 169:1669
244. Porter DL, Antin JH (1999) The graft versus leukemia effects of allogeneic cell therapy. Annu Rev Med 50:369
245. Poznansky MC, Evans RH, Foxall RB, Olszak IT, Piascik AH, Hartman KE, Brander C, Meyer TH, Pykett MJ, Chabner KT, Kalams SA, Rosenzweig M, Scadden DT (2000) Efficient generation of human T cells from a tissue-engineered thymic organoid. Nat Biotechnol 18:729
246. Prigozhina TB, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S (2002) Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol 30:89
247. Provinciali M, Argentati K, Tibaldi A (2000) Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 7:624
248. Pularski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell based tumor vaccines. Cancer Res 58:1486
249. Rajagopalan S, Long EO (1999) A human histocompatibility leukocyte antigen (HLA) G specific receptor expressed on all natural killer cells. J Exp Med 189:1093
250. Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S (2002) Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 188:164
251. Ratta M, Rondelli D, Fortuna A, Curti A, Fogli M, Fagnoni F, Martinelli G, Terragna C, Tura S, Lemoli RM (1998) Generation and functional characterization of human dendritic cells derived from CD34 cells mobilized into peripheral blood, comparison with bone marrow CD34+ cells. Br J Haematol 101:756
252. Raziuddin A, Longo DL, Mason L, Ortaldo JR, Bennett M, Murphy WJ (1998) Differential effects of the rejection of bone marrow allografts by the depletion of activating versus inhibiting Ly 49 natural killer cell subsets. J Immunol 160:87
253. Reisner Y, Bachar-Lustig E, Li HW, Aversa F, Velardi A, Martelli MF (1999) The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Ann N Y Acad Sci 872:336
254. Reiss U, Bolotin E (2002) New approaches to hematopoietic cell transplanation in oncology. Pediatr Clin North Am 49:1437
255. Restifo NP (2001) Countering the 'counterattack' hypothesis. Nat Med 7:259
256. Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, Theoret MR, Touloukian CE (2002) Assumptions of the tumor 'escape' hypothesis. Semin Cancer Biol 12:81
257. Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D (2001) Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 279:354
258. Robinson HL (1999) DNA vaccines, basic mechanisms and immune responses. Int J Mol Med 4:549
259. Romagnani S (1992) Induction of TH1 and TH2 responses, a key role for the 'natural' immune response? Immunol Today 13:379
260. Roman J, Alvarez MA, Torres A (2000) Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Haematologica 85:1072
261. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 195:2097
262. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7:2277
263. Saenz-Badillos J, Amin SP, Granstein RD (2001) RNA as a tumor vaccine, a review of the literature. Exp Dermatol 10:143
264. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18
265. Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP (1998) Dendritic cell based immunotherapy of prostate cancer. Crit Rev Immunol 18:109
266. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22
267. Schadendorf D (2002) Gene-based therapy of malignant melanoma. Semin Oncol 29:503
268. Schendel DJ, Frankenberger B, Jantzer P, Cayeux S, Nobetane RE, Willimsky G, Maget B, Pohla H, Blankenstein T (2000) Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 7:2007
269. Schleuning, M (2000) Adoptive allogeneic immunotherapy: history and future perspectives. Transfus Sci 23:133
270. Schoenberger SP, Toes REM, van derVoort EIH, Offringa R, Melief CJ (1998) T cell help for cytotoxic T lymphocytes is mediated by CD40 CD40L interactions. Nature 393:480
271. Schreiber H, Wu TH, Nachman J, Kast WM (2002) Immunodominance and tumor escape. Semin Cancer Biol 12:25
272. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279
273. Seliger B, Harders C, Wollscheid U, Staege MS, Reske-Kunz AB, Huber C (1996) Suppression of MHC class I antigens in oncogenic transformants, association with decreased recognition by cytotoxic T lymphocytes. Exp Hematol 24:1275
274. Sempowski GD, Hale LP, Sundy JS, Massey JM, Koup RA, Douek DC, Patel DD, Haynes BF (2000) Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy. J Immunol 164:2180
275. Shen Z, Reznikoff G, Dranoff G, Rock KL (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158:2723
276. Sherman LA, Theobald M, Morgan D, Hernandez J, Bacik I, Yewdell J, Bennink J, Biggs J (1998) Strategies for tumor elimination by cytotoxic T lymphocytes. Crit Rev Immunol 18:47
277. Singhal S, Mehta J (1999) Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant. 23:637
278. Sirard JC, Niedergang F, Krahenbuhl JP (1999) Live attenuated Salmonella, a paradigm of mucosal vaccines. Immunol Rev 171:5
279. Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M (2003) CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol 170:1490
280. Slavin S, Or R, Prighozina T, Gurevitch O, Aker M, Panighari S, Shapira M, Nagler A (2000) Immunotherapy of hematologic malignancies and metastaic solid tumors in experimental animals and man. Bone Marrow Transplant 25:54
281. Slavin S, Nagler A, Shiapria MY, Aker M, Gabriel C, Or R (2002) Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. J Clin Immunol 22:64
282. Slavin S, Morecki S, Weiss L, Or R (2003) Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Crit Rev Oncol Hematol 46:139
283. Smith JR, Pereira-Smith OM (1996) Replicative senescence: implications for in vivo aging and tumor suppression. Science 273:63
284. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850
285. Sosman JA, Sondak VK (2003) Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2:353
286. Spitzer TR (2000) Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 5:215
287. Sponaas A, Carstens C, Koch N (1999) C terminal extension of the MHC class II associated invariant chain by an antigenic sequence triggers activation of naive T cells. Gene Ther 6:1826
288. Sreekumar A, Chinnaiyan AM (2002) Using protein microarrays to study cancer. Biotechniques 1:46
289. St George JA (2003) Gene therapy progress and prospects: adenoviral vectors. Gene Ther 10:1135
290. Storb R (2003) Allogeneic hematopoietic stem cell transplantation - Yesterday, today, and tomorrow. Exp Hematol 31:1
291. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63:2127
292. Sullivan DH, Carter WJ (1994) Insulin-like growth factor I as an indicator of protein-energy undernutrition among metabolically stable hospitalized elderly. J Am Coll Nutr 13:184
293. Sunday ME, Isselbacher KJ, Gattoni-Celli S, Willett CG (1989) Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene. Proc Natl Acad Sci U S A 86:4700
294. Sundstrom B, Ansari AA (1995) Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts. Transpl Immunol 3:273
295. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH (2003) Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 21:713
296. Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, Pena J, Solana R (2000) Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev 121:77
297. Tarte K, Klein B (1999) Dendritic cell based vaccine, a promising approach for cancer immunotherapy. Leukemia 13:653
298. Teshima T, Mach N, Hill GR, Pan L, Gillessen S, Dranoff G, Ferrara JLM (2001) Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 61:162
299. teVelde AA, Figdor CG (1992) Monocyte mediated cytotoxic activity against melanoma. Melanoma Res 1:303
300. Thomas MC, Greten TF, Pardoll DM, Jaffee EM (1998) Enhanced tumor protection by granulocyte macrophage colony stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 10:835
301. Timmerman JM (2003) Immunotherapy for lymphomas. Int J Hematol 77:444
302. Tindle RW (2002) Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2:59
303. Topalian SL (1994) MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 6:741
304. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E (1997) Identification of subdominant CTL epitopes of the gp100 melanoma associated tumor antigen by primary in vitro immunization with peptide pulsed dendritic cells. J Immunol 158:1796
305. Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN (2002) Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 188:122
306. Uhrberg M, Valiante NM, Young NT, Lanier LL, Phillips JH, Parham P (2001) The repertoire of killer cell Ig like receptor and CD94,NKG2A receptors in T cells, clones sharing identical alpha beta TCR rearrangement express highly diverse killer cell Ig like receptor patterns. J Immunol 166:3923
307. Unanue ER (1997) Studies in listeriosis show the strong symbiosis between the innate cellular system and the T cell response. Immunol Rev 158:11
308. Vales-Gomez M, Reyburn H, Strominger J (2000) Interaction between the human NK receptors and their ligands. Crit Rev Immunol 20:223
309. van Broekhoven CL, Altin JG (2002) A novel approach for modifying tumor cell-derived plasma membrane vesicles to contain encapsulated IL-2 and engrafted costimulatory molecules for use in tumor immunotherapy. Int J Cancer 98:63
310. Van den Brink MR, Burakoff SJ (2002) Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2:273
311. vanBesien K, Keralavarma B, Devine S, Stock W (2001) Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia 15:1317
312. Velders MP, Schreiber H, Kast WM (1998) Active immunization against cancer cells, impediments and advances. Semin Oncol 25:697
313. Vely F, Peyrat M, Couedel C, Morcet J, Halary F, Davodeau F, Romagne F, Scotet E, Saulquin X, Houssaint E, Schleinitz N, Moretta A, Vivier E, Bonneville M (2001) Regulation of inhibitory and activating killer cell Ig like receptor expression occurs in T cells after termination of TCR rearrangements. J Immunol 166:2487
314. Verfuerth S, Peggs K, Vyas P, Barnett L, O'Reilly RJ, Mackinnon S (2000) Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T cell depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T cell repertoire. Blood 95:3990
315. Vicari AP, Caux C, Trinchieri G (2002) Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 12:33-42
316. Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157
317. Vindelov L (2001) Allogeneic bone marrow transplantation with reduced conditioning. Eur J Haematol 66:73
318. Vogelsang GB (2001) How I treat chronic graft versus host disease. Blood 97:1196
319. Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S (1999) Selective histocompatibility leukocyte antigen (HLA) A2 loss caused by aberrant pre mRNA splicing in 624MEL28 melanoma cells. J Exp Med 190:205
320. Watts C (1997) Capture and processing of exogenous antigens for presentation on MHC molecules. Ann Rev Immunol 15:821
321. Weiskirch LM, Pan Z.K, Paterson Y (2001) The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector mechanisms. Clin Immunol 98:346
322. Whisler RL, Beiqing L, Chen M (1996) Age-related decrease in IL-2 production by human T cells are associated with impaired activation of nuclear transcriptional factors AP-1 and NF-AT. Cell Immunol 169:185
323. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM (1995) Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92:1671
324. Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555
325. Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Silletti S, Lode HN, Dolman CS, Gillies SD, Reisfeld RA (2001) A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 167:4560
326. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL (2001) Vaccination of malignant glioma patients with peptide pulsed dendritic cells elicits systemic cytotoxicity and intracranial T cell infiltration. Cancer Res 61:842
327. Yu XZ, Bidwell SJ, Martin PJ, Anasetti C (2001) Anti CD3 epsilon F(ab′)2 prevents graft versus host disease by selectively depleting donor T cells activated by recipient alloantigens. J Immunol 166:5835
328. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H (1997) Antigen localization regulates immune responses in a dose and time dependent fashion, a geographical view of immune reactivity. Immul Rev 156:199
329. Zöller M (2003) Tumor vaccination after allogeneic bone marrow cell reconstitution of the non-myeloablatively conditioned tumor-bearing host. J Immunol, 171:6941
330. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa R, Melief CJ (2002) Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 62:6187